ARDX
Ardelyx Inc.
$6.05
+$0.21(+3.60%)
50
Overall
40
Value
72
Tech
39
Quality
Market Cap
$1.40B
Volume
9.84M
52W Range
$3.49 - $8.40
Target Price
$16.33
Company Overview
| Mkt Cap | $1.40B | Price | $6.05 |
| Volume | 9.84M | Change | +3.60% |
| P/E Ratio | -22.7 | Open | $5.90 |
| Revenue | $407.3M | Prev Close | $5.84 |
| Net Income | $-61.6M | 52W Range | $3.49 - $8.40 |
| Div Yield | N/A | Target | $16.33 |
| Overall | 50 | Value | 40 |
| Quality | 39 | Technical | 72 |
No chart data available
About Ardelyx Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest News
Ardelyx Shareholders Approve Equity Plan Amendment and Directors
TipRanks Auto-Generated Newsdesk•3 days ago
Ardelyx Advances Long-Term Tenapanor Trial in Chronic Constipation: What Investors Should Watch
TipRanks Clinical-Trials-Auto-Generated Newsdesk•17 days ago
Ardelyx Advances Long-Term Tenapanor Trial in Chronic Constipation: What Investors Should Watch
TipRanks Clinical-Trials-Auto-Generated Newsdesk•17 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARDX | $6.05 | +3.6% | 9.84M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |